|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
606.85
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | -42.57 | -7.87 | 7.68 | -8.00 | 1.00 | CEPS(Rs) | -27.52 | 3.94 | 18.46 | 2.10 | 9.77 | DPS(Rs) | 0.00 | 4.00 | 4.00 | 4.00 | 4.00 | Book NAV/Share(Rs) | 336.94 | 378.00 | 382.01 | 375.30 | 387.60 | Tax Rate(%) | -7.39 | 36.10 | 17.61 | 11.75 | 132.63 | Margin Ratios | | | | | | Core EBITDA Margin(%) | -8.66 | -4.62 | 8.49 | -10.02 | -6.28 | EBIT Margin(%) | -25.15 | -8.98 | 5.96 | -6.91 | -2.17 | Pre Tax Margin(%) | -26.02 | -9.20 | 5.84 | -7.06 | -2.23 | PAT Margin (%) | -27.95 | -5.88 | 4.81 | -6.23 | 0.73 | Cash Profit Margin (%) | -18.06 | 2.94 | 11.56 | 1.63 | 7.10 | Performance Ratios | | | | | | ROA(%) | -9.98 | -1.78 | 1.76 | -1.86 | 0.23 | ROE(%) | -11.91 | -2.07 | 2.03 | -2.10 | 0.26 | ROCE(%) | -10.21 | -3.08 | 2.50 | -2.32 | -0.76 | Asset Turnover(x) | 0.36 | 0.30 | 0.37 | 0.30 | 0.32 | Sales/Fixed Asset(x) | 0.71 | 0.77 | 1.04 | 0.92 | 1.21 | Working Capital/Sales(x) | 1.19 | 0.89 | 1.20 | 0.78 | 0.61 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 1.41 | 1.30 | 0.96 | 1.09 | 0.82 | Receivable days | 145.14 | 143.48 | 110.99 | 132.06 | 106.19 | Inventory Days | 160.11 | 163.90 | 113.93 | 119.00 | 90.89 | Payable days | 160.92 | 194.36 | 201.52 | 235.09 | 217.37 | Valuation Parameters | | | | | | PER(x) | 0.00 | 0.00 | 40.27 | 0.00 | 194.50 | PCE(x) | -10.51 | 66.04 | 16.75 | 72.13 | 19.92 | Price/Book(x) | 0.86 | 0.69 | 0.81 | 0.40 | 0.50 | Yield(%) | 0.00 | 1.54 | 1.29 | 2.64 | 2.06 | EV/Net Sales(x) | 1.85 | 1.97 | 1.89 | 0.97 | 1.22 | EV/Core EBITDA(x) | -38.76 | -1,251.83 | 14.84 | 102.28 | 28.92 | EV/EBIT(x) | -7.34 | -21.97 | 31.67 | -14.00 | -56.22 | EV/CE(x) | 0.69 | 0.60 | 0.79 | 0.29 | 0.39 | M Cap / Sales | 1.90 | 1.94 | 1.94 | 1.18 | 1.42 | Growth Ratio | | | | | | Net Sales Growth(%) | 13.73 | -16.11 | 24.27 | -6.54 | -21.41 | Core EBITDA Growth(%) | -3,336.70 | -101.04 | 1,568.75 | -78.99 | -98.76 | EBIT Growth(%) | -218.53 | -226.48 | 207.06 | -198.29 | -100.64 | PAT Growth(%) | -440.69 | -202.49 | 196.03 | -899.72 | -99.72 | EPS Growth(%) | -440.69 | -202.49 | 196.03 | -899.48 | -99.72 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.04 | 0.05 | 0.00 | 0.01 | 0.00 | Current Ratio(x) | 3.33 | 4.42 | 3.51 | 4.32 | 6.82 | Quick Ratio(x) | 2.09 | 2.93 | 2.47 | 3.41 | 5.81 | Interest Cover(x) | -28.75 | -40.82 | 51.47 | -48.78 | -33.97 | Total Debt/Mcap(x) | 0.05 | 0.07 | 0.00 | 0.01 | 0.00 |
|
|
|
|
|
|